Treatment for pityriasis rubra pilaris (PRP)
Treatments studied
Part of Skin clinical trials.
This trial tests a new medicine called Bimekizumab (Bimzelx) to see if it improves PRP, a rare skin condition that causes red, scaly patches. If you have moderate to severe PRP, this treatment might help clear your skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a formal diagnosis of PRP (pityriasis rubra pilaris), confirmed by a doctor.
- Your skin condition is severe enough that your doctor recommends systemic therapy (medicine that works throughout the body).
- At least 10% of your body is covered by PRP.
- You are in generally good health overall.
- You are willing to follow the study plan and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
This study tests a medication called bimekizumab to see if it helps people with pyoderma gangrenosum, a painful skin condition that causes deep ulcers. If you qualify, you'll receive the treatment and be monitored for about a year.
This study tests a new medicine called remibrutinib to see if it can reduce severe itching that has no clear cause. It aims to help people whose daily itching is very intense and not relieved by standard creams.
This study tests an experimental drug called remibrutinib (taken as a pill) to see if it can safely reduce the redness and bumps caused by papulopustular rosacea. It is for people with moderate to severe symptoms who have not had success with other treatments.
This study tests a drug called lebrikizumab for people with severe prurigo nodularis, a condition with very itchy skin bumps. The drug is given as an injection and aims to reduce itching and clear the bumps faster.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
Hear when a new Pityriasis Rubra Pilaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.